Advertisement

Related Videos

Welcome and Introduction to Vi3C

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Aug
03
Today In Oncology
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo